Progress feels a little like driving on a motorway.

When the road is clear and the car is moving quickly, it is natural to assume you have plenty of options. After all, you are travelling faster and covering more ground than before.

But there is a small paradox in motorway driving that anyone who has missed a junction will recognise. The faster you move, the fewer choices you actually have.

You cannot simply turn around. Exits appear only at certain points. And once you have passed one, your next opportunity to change direction may be several miles away.

Progress in MedTech works in a surprisingly similar way.

When milestones are being achieved and momentum feels strong, the organisation appears to be gaining freedom. Engineering advances, regulatory conversations move forward, and the commercial narrative begins to solidify.

Yet each of those steps often commits the company slightly more firmly to a particular path. From the outside, everything looks like progress. Inside the boardroom, however, a quieter question sometimes emerges.

Not “Are we moving forward?”

But something more subtle.

“Are we still free to choose our next move?”

The moment everything looked correct

I once watched a board meeting where the quarterly update could only be described as encouraging.

The engineering team had delivered a significant milestone slightly ahead of schedule. The regulatory strategy appeared stable. Clinical advisers were supportive and the early market conversations sounded positive.

In other words, the company was doing precisely what boards hope their companies will do.

At one point, however, the Chair paused and asked what seemed like a simple question.

“If we discovered something new about the market in twelve months’ time,” he said, “how easily could we change direction?”

It was not an aggressive question. It was asked almost casually.

The responses that followed were equally calm.

The CTO explained that the current architecture assumed a particular regulatory pathway. The clinical lead added that the trial design had been structured around that same assumption. The commercial team pointed out that investor messaging had already begun to reflect the same story.

Nothing had gone wrong. But several decisions that had once looked independent had quietly aligned with one another. Changing direction was still possible, of course.

It was simply no longer easy.

The Notified Body conversation

A similar realisation sometimes happens in a much quieter setting.

A MedTech company had spent nearly two years refining the regulatory pathway for a promising diagnostic platform. The engineering roadmap had been designed around that pathway, and the clinical evidence plan had followed accordingly.

When the leadership team finally sat down with their Notified Body for an early dialogue, the meeting itself went well. The technology was respected and the preparation was clearly thorough.

At one point, however, the reviewer made an observation that sounded almost casual.

“If you intend to make that claim,” they said, “the classification might move up a level.”

It was not a rejection, nor even criticism.

But that small shift meant the clinical evidence requirements would change. The regulatory timeline would stretch. Certain engineering decisions would need revisiting.

And because the product design, clinical programme, and investor narrative had already settled around the original pathway, what had seemed like straightforward progress suddenly revealed itself as commitment.

Nothing had been done incorrectly. The company had simply moved forward faster than it realised.

Why progress can narrow the field

Boards often assume that progress increases optionality. After all, reaching milestones feels like gaining ground.

Yet each milestone in MedTech usually carries an invisible side effect. It shapes architecture, regulatory interpretation, and commercial narrative at the same time.

Engineering choices influence which regulatory claims remain feasible. Clinical trial designs signal how regulators will interpret evidence. Commercial positioning subtly commits the company to a particular story about its future.

None of these decisions are careless. In fact, they are usually very sensible. But sensible decisions have a tendency to accumulate. And when several sensible decisions begin reinforcing each other, optionality can quietly shrink.

The investor update that sealed the narrative

One company experienced this during what was meant to be a routine investor update.

The CEO was presenting encouraging data from early clinical work, and the board discussion turned to how the platform might evolve over time. An investor asked a question that sounded optimistic rather than sceptical.

“If this indication proves successful,” they said, “could the platform support other applications later?”

The CEO replied honestly that the technology could, in theory, expand into several adjacent areas. But the conversation that followed revealed something interesting.

Engineering had already optimised the system for the current use case. The regulatory pathway assumed that indication would remain central. The commercial narrative presented during the funding round was built around that specific market.

In other words, the organisation had gradually begun behaving as though one future was already decided. It had not been forced into that position. It had arrived there through success.

Why boards rarely notice the shift

Boards do not overlook these dynamics because they are inattentive but because progress is reassuring.

When delivery teams present coherent plans, when risks appear contained, and when everyone around the table seems aligned, questioning direction can feel unnecessarily pessimistic.

After all, progress is supposed to be good news.

The small irony is that success creates momentum of its own, and momentum has a curious habit of converting choices into commitments without announcing when that conversion has taken place.

By the time the narrowing of options becomes visible, the organisation has usually invested considerable energy, capital, and reputation into the chosen path.

Changing direction remains possible. It simply becomes more expensive, both financially and psychologically.

Leadership quietly shapes flexibility

This is where leadership decisions begin to matter more than they first appear. Some executives instinctively protect optionality. They are comfortable acknowledging uncertainty and building systems that remain adaptable longer than seems efficient.

Others prefer clarity and decisive progress. They aim to align the organisation quickly around a single narrative and execute against it. Neither instinct is wrong.

But when a company approaches scale, the difference becomes more noticeable. One style preserves room to adapt. The other reduces ambiguity early, which can make progress faster but future choices narrower.

The consequences of that difference often appear long after the decision has been praised.

The question experienced boards tend to ask

The danger in MedTech is rarely that organisations make the wrong decision. More often, they make the right decision slightly earlier than they realise they should.

A sensible regulatory pathway is chosen. A promising clinical indication becomes the focus. Engineering aligns the platform around that assumption. The commercial narrative settles into a compelling story.

Each step makes perfect sense.

Yet when several sensible decisions begin reinforcing one another, the organisation gradually moves from exploration to commitment without anyone quite noticing when the shift occurred.

Progress has been real. But freedom has quietly narrowed.

Experienced boards eventually learn to watch for that moment.

Not because commitment is dangerous, but because in MedTech the most valuable strategic asset is often the ability to change course before the market, the regulator, or the science forces the decision for you.

The companies that scale most cleanly are rarely those that avoid commitment.

They are the ones that recognise when progress is beginning to harden into permanence, and pause long enough to decide whether that permanence is truly the path they want.

---

FAQs

Is this article suggesting progress is a bad thing?

Not at all. Progress is essential, particularly in a field as complex as MedTech. The article simply highlights a subtle dynamic: progress often carries hidden commitments. Engineering decisions, regulatory strategies, and commercial positioning can gradually reinforce one another until the organisation finds itself more committed to a particular path than it initially intended.

Why do boards sometimes notice this narrowing of options later than expected?

Because progress is reassuring. When milestones are being met and teams appear aligned, questioning direction can feel unnecessary. It is only when new information appears, perhaps from a regulator, a competitor, or a clinical insight, that boards realise how much of the future trajectory has already been shaped.

Where does leadership fit into this question of optionality?

Leadership plays a surprisingly large role. Certain executives instinctively design systems that remain adaptable longer than seems necessary. Others prefer clarity and decisive commitment. Both instincts have advantages, but when a company approaches scale, the ability of leaders to recognise and manage these moments of commitment becomes extremely important.

How does this relate to your work with MedTech boards?

Much of my work involves helping boards think about leadership decisions through the lens of long-term valuation rather than short-term operational needs. Senior appointments, particularly roles like Chief Medical Officer or Chief Technology Officer, can significantly influence how flexible an organisation remains as it scales. My role is often to help boards identify and select leaders who have already navigated similar terrain and understand the strategic consequences of those decisions.

If a board is thinking about these issues, how can they start a conversation with you?

The best starting point is usually a short, informal conversation about the company’s current stage of scale and the leadership challenges it expects to face over the next few years. If this article resonates and you would like to explore the topic further, you are welcome to reach out to me directly on LinkedIn or through my website to arrange a brief discussion.